
Experience
MannKind to Acquire scPharmaceuticals for up to $360 Million
August 25, 2025
Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million
Related contacts
Related Practices & Industries
SiteOne Therapeutics to Be Acquired by Eli Lilly for up to $1 Billion
May 28, 2025
Cooley advised SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, on its acquisition by Eli Lilly.
Related contacts
Related Practices & Industries
EsoBiotec Announces up to $1 Billion Acquisition by AstraZeneca
March 17, 2025
Cooley advised EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, on its definitive agreement to be acquired by AstraZeneca (London Stock Exchange/Nasdaq Stockholm/Nasdaq: AZN) for up to $1 billion on a cash- and debt-free basis.
Related contacts
Related Practices & Industries
Poseida Therapeutics Announces Agreement to Be Acquired by Roche for up to $1.5 Billion
November 26, 2024
Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.
Related contacts
Related Practices & Industries
ProfoundBio Announces $1.8 Billion Acquisition by Genmab
April 3, 2024
Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.
Related contacts
Related Practices & Industries
Related news and events
Admissions and credentials
California
New York
Rankings and accolades
The Legal 500 US: M&A: Large Deals ($1bn+) (2024 – 2025)